Why the study?
Do novel oral anticoagulants prevent stroke compared to vitamin K antagonists in patients with nonvalvular atrial fibrillation?
Population
Patients with nonvalvular atrial fibrillation (NVAF)
Comparison
Novel oral anticoagulants vs Vitamin K antagonists (VKAs) such as warfarin
Design
Review
Authors
Loading...
Practical challenges warrant individualized NOAC decisions in older NVAF patients with renal impairment; leaves open optimal reversal strategies.
Do novel oral anticoagulants prevent stroke compared to vitamin K antagonists in patients with nonvalvular atrial fibrillation?
This review highlights the pharmacologic advantages of NOACs over warfarin for stroke prevention in NVAF, while emphasizing the need to manage practical challenges like renal dysfunction and bleeding reversal.
Steven Deitelzweig (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: